Bullfrog AI Holdings Inc. (BFRG)
BFRG trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1829247/000149315226011644/0001493152-26-011644-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BFRG on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2023 |
| SEC CIK | 0001829247 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $117K |
| Net income | -$6.5M |
| Operating income | -$6.6M |
| Net margin | -5569.6% |
| Operating margin | -5652.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $2.2M |
| Total assets | $2.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 77.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about our ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $6.9M cash; operating cash flow -$1.4M a quarter. | Report 2026-06-30 |
| Shares outstanding | 18,693,280 (2026-11-12); 11,409,745 a year earlier; 6,094,644 three years earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-04-01 |
| Exchange deficiency notices, 12 months | 3 (8-K item 3.01) | 8-K 2026-08-20 |
| Auditor | M&K CPAS, PLLC, The Woodlands, Texas, United States | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $72K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $215K | -$1.4M | -$1.5M | $6.9M | $90K | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$1.6M | -$1.7M | $5.1M | $134K | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-12-31 | $0 | -$1.5M | -$1.2M | $2.2M | No debt tags | $117K | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | $83K | -$1.6M | -$1.1M | $2.0M | $56K | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $33K | -$1.4M | -$1.4M | $2.5M | $110K | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$2.0M | -$1.8M | $3.8M | $164K | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-12-31 | Not filed | -$1.7M | -$1.3M | $5.4M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
| Q3 2024 2024-09-30 | Not filed | -$1.8M | -$1.2M | $4.2M | $172K | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-07-06 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-08-20 |
| Latest proxy | DEFA14A | 2026-05-01 |
Source: SEC EDGAR submissions feed, 206 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.6% |
| 1 month | -4.7% |
| 3 months | -8.3% |
| Year to date | -38.6% |
| 1 year | -45.8% |
| From 52-week high | -67.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| BFRGW | Bullfrog AI Holdings Inc. Warrants | $0.1050 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PHIO | Phio Pharmaceuticals Corp. | $0.7522 | -2.44% | $9.0M |
| GDTC | CytoMed Therapeutics Limited | $0.7739 | -6.68% | $9.2M |
| LEXX | Lexaria Bioscience Corp. | $4.41 | -0.68% | $9.3M |
| VTGN | Vistagen Therapeutics Inc. | $0.1843 | +2.11% | $8.5M |
| CALC | CalciMedica Inc. | $1.19 | -1.65% | $8.2M |
| AEON | AEON Biopharma Inc. | $0.1407 | -8.04% | $10.1M |
| MTVA | MetaVia Inc. | $1.21 | -7.31% | $8.1M |
| CLRB | Cellectar Biosciences Inc. | $1.01 | -11.40% | $10.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier